Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by InterVenn Biosciences

InterVenn Receives AMA PLA Code for Non-Invasive Ovarian Cancer Diagnostic
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
From InterVenn Biosciences
Via Business Wire
InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From InterVenn Biosciences
Via Business Wire
Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present at the 20th Annual Morgan Stanley Global Healthcare Conference
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
From InterVenn Biosciences
Via Business Wire
InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies
From InterVenn Biosciences
Via Business Wire
InterVenn to Present New Clinical Data at ASCO 2022 on Using Glycoproteomics as Powerful Liquid Biopsy Tests for Early Detection of Cancer and Prediction of Checkpoint Inhibitor Treatment Benefit
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present at the Bank of America 2022 Healthcare Conference
From InterVenn Biosciences
Via Business Wire
InterVenn to Showcase Novel Translational Research Opportunities Based on Glycoproteomics at AACR 2022
From InterVenn Biosciences
Via Business Wire
Veteran Healthcare Executive and Reimbursement Expert Joins InterVenn Biosciences’ Board of Advisors
From InterVenn Biosciences
Via Business Wire
InterVenn Promotes Klaus Lindpaintner to InterVenn Distinguished Scientist; Appoints Tillman Pearce as Chief Medical Officer
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Names Brian Hogan as Chief Financial Officer
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
From InterVenn Biosciences
Via Business Wire
InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Participate at Two Upcoming Investor Conferences in November
From InterVenn Biosciences
Via Business Wire
InterVenn Presents Results at American Society for Mass Spectrometry Conference Demonstrating that Differential Peripheral Blood Glycoproteomic Signatures are Associated with Symptomatic vs. Asymptomatic Course of COVID-19 Infection
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test
From InterVenn Biosciences
Via Business Wire
InterVenn Biosciences Welcomes Former U. S. Surgeon General Regina Benjamin, MD, MBA to the Company’s Board of Advisors
From InterVenn Biosciences
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.